(Q38239286)

31 August 2017

title

Fc receptor-dependent mechanisms of monoclonal antibody therapy of cancer (English)

1 reference

31 August 2017

1 reference

2

Marjolein van Egmond

0 references

author name string

Jantine E Bakema

series ordinal

1

1 reference

31 August 2017

publication date

1 January 2014

1 reference

Current Topics in Microbiology and Immunology

31 August 2017

published in

1 reference

31 August 2017

volume

382

1 reference

31 August 2017

page(s)

373-392

1 reference

Neutrophils mediate antibody-induced antitumor effects in mice.

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

The future of anti-CD20 monoclonal antibodies: are we making progress?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Understanding rituximab function and resistance: implications for tailored therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Neutrophil function: from mechanisms to disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Targeting FcαRI on polymorphonuclear cells induces tumor cell killing through autophagy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

The high-affinity IgG receptor, FcgammaRI, plays a central role in antibody therapy of experimental melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Serum-free production and purification of chimeric IgA antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

IgA EGFR antibodies mediate tumour killing in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Fc receptors are required in passive and active immunity to melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

The defensive alliance between neutrophils and NK cells as a novel arm of innate immunity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Clinical experience with CD64-directed immunotherapy. An overview

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Unique carbohydrate-carbohydrate interactions are required for high affinity binding between Fc RIII and antibodies lacking core fucose

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Mechanisms of killing by anti-CD20 monoclonal antibodies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Granzymes A and B are not expressed in human neutrophils

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Tumor-associated macrophages promote invasion while retaining Fc-dependent anti-tumor function.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Macrophages eliminate circulating tumor cells after monoclonal antibody therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Surgery-induced reactive oxygen species enhance colon carcinoma cell binding by disrupting the liver endothelial cell lining

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Granzyme A: an additional weapon of human polymorphonuclear neutrophils (PMNs) in innate immunity?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Intimate cell conjugate formation and exchange of membrane lipids precede apoptosis induction in target cells during antibody-dependent, granulocyte-mediated cytotoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Neutrophil depletion impairs natural killer cell maturation, function, and homeostasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Complement in cancer and cancer immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Fcalpha receptor (CD89) mediates the development of immunoglobulin A (IgA) nephropathy (Berger's disease). Evidence for pathogenic soluble receptor-Iga complexes in patients and CD89 transgenic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Engineered antibody Fc variants with enhanced effector function

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Distinct role of macrophages in different tumor microenvironments

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Neutrophils in the activation and regulation of innate and adaptive immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Advances in bispecific biotherapeutics for the treatment of cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Polymorphonuclear neutrophils deliver activation signals and antigenic molecules to dendritic cells: a new link between leukocytes upstream of T lymphocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Human neutrophils lack granzyme A, granzyme B, and perforin

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Autophagy fights disease through cellular self-digestion

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Interleukin-15 enhances rituximab-dependent cytotoxicity against chronic lymphocytic leukemia cells and overcomes transforming growth factor beta-mediated immunosuppression

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Exploring the full spectrum of macrophage activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Divergent immunoglobulin g subclass activity through selective Fc receptor binding

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Enhanced FcαRI-mediated neutrophil migration towards tumour colonies in the presence of endothelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Experimental Antibody Therapy of Liver Metastases Reveals Functional Redundancy between Fc RI and Fc RIV

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Role of IgG Fc Receptors in Monoclonal Antibody Therapy of Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Crosstalk between human IgG isotypes and murine effector cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Anti-CD20 IgA can protect mice against lymphoma development: evaluation of the direct impact of IgA and cytotoxic effector recruitment on CD20 target cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Evidence for a cross-talk between human neutrophils and Th17 cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Brentuximab Vedotin in CD30+ Lymphomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

The future of antibodies as cancer drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Antibody therapy of cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

The end of autophagic cell death?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Monoclonal antibodies for the treatment of cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Antibody-drug conjugates in cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Antibody therapeutics in cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Polymorphonuclear granulocytes induce antibody-dependent apoptosis in human breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Neutrophil granulocytes are required for effective Bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Experimentally induced liver metastases from colorectal cancer can be prevented by mononuclear phagocyte-mediated monoclonal antibody therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Blocking alpha2 integrins on rat CC531s colon carcinoma cells prevents operation-induced augmentation of liver metastases outgrowth

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Neutrophils as effector cells for antibody-based immunotherapy of cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Close encounters of neutrophils and DCs

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Neutrophils mediate immune modulation of dendritic cells through glycosylation-dependent interactions between Mac-1 and DC-SIGN.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Adjuvant treatment of colon cancer: what is next?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Mac-1 (CD11b/CD18) is crucial for effective Fc receptor-mediated immunity to melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Granzyme B and perforin: constitutive expression in human polymorphonuclear neutrophils

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Antibody-based immunotherapy of cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Circulating tumour cells during laparoscopic and open surgery for primary colonic cancer in portal and peripheral blood

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

Application of a novel inhibitor of human CD59 for the enhancement of complement-dependent cytolysis on cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

CD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_17

10.1007/978-3-319-07911-0_17

31 March 2020

Identifiers

DOI

1 reference

31 August 2017

1 reference